- Home
- IH vs AGEN Comparison
IH vs AGEN Comparison
Compare IH & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IH
- AGEN
- Stock Information
- Founded
- IH 1996
- AGEN 1994
- Country
- IH China
- AGEN United States
- Employees
- IH N/A
- AGEN N/A
- Industry
- IH Other Consumer Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IH Real Estate
- AGEN Health Care
- Exchange
- IH Nasdaq
- AGEN Nasdaq
- Market Cap
- IH 88.8M
- AGEN 96.2M
- IPO Year
- IH 2020
- AGEN 2000
- Fundamental
- Price
- IH $1.67
- AGEN $3.48
- Analyst Decision
- IH
- AGEN Buy
- Analyst Count
- IH 0
- AGEN 3
- Target Price
- IH N/A
- AGEN $10.50
- AVG Volume (30 Days)
- IH 12.2K
- AGEN 419.4K
- Earning Date
- IH 02-27-2025
- AGEN 03-13-2025
- Dividend Yield
- IH N/A
- AGEN N/A
- EPS Growth
- IH N/A
- AGEN N/A
- EPS
- IH 0.28
- AGEN N/A
- Revenue
- IH $134,002,994.00
- AGEN $160,427,000.00
- Revenue This Year
- IH $15.90
- AGEN N/A
- Revenue Next Year
- IH $8.64
- AGEN $36.13
- P/E Ratio
- IH $6.00
- AGEN N/A
- Revenue Growth
- IH N/A
- AGEN 59.00
- 52 Week Low
- IH $1.47
- AGEN $2.50
- 52 Week High
- IH $2.94
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- IH 48.69
- AGEN 58.60
- Support Level
- IH $1.60
- AGEN $3.08
- Resistance Level
- IH $1.74
- AGEN $3.29
- Average True Range (ATR)
- IH 0.10
- AGEN 0.26
- MACD
- IH 0.00
- AGEN 0.05
- Stochastic Oscillator
- IH 52.17
- AGEN 80.36
About IH iHuman Inc.
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. The majority of iHuman Inc's revenue comes from mainland China.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).